Rasagiline: A review of its use in the treatment of idiopathic parkinson's disease

CNS Drugs

Volumn 28, Issue 11, 2014, Pages 1083-1097

  McCormack, Paul L ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; RASAGILINE; INDAN DERIVATIVE; MONOAMINE OXIDASE INHIBITOR;

ARTHRALGIA; ASTHENIA; BACKACHE; BASAL CELL CARCINOMA; COMMUNITY CARE; COMPARATIVE STUDY; DIZZINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; FALLING; HEADACHE; HUMAN; HYPERTENSION; INFECTION; INJURY; MELANOMA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL PAIN; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SKIN CARCINOMA; SOMNOLENCE; TREATMENT DURATION; TREMOR; CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION; DRUG INTERACTION; ECONOMICS; ENZYMOLOGY; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; INDANS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84919930604     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0206-y     Document Type: Review

References (52)

1. Clarke CE. Parkinson's disease. BMJ. 2007;335(7617):441-5.
2. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-83.
3. Beitz JM. Parkinson's disease: a review. Front Biosci. 2014;6:65-74.
4. Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol. 2005;45(8):878-94.
5. US FDA. Azilect (rasagiline mesylate): US prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/021641s016s017lbl.pdf. Accessed 12 Sep 2014.
6. Reynolds GP, Riederer P, Sandler M, et al. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J Neural Transm. 1978;43(3-4):271-7.
7. Riederer P, Konradi C, Schay V, et al. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of l-deprenyl. Adv Neurol. 1987;45:111-8.
8. European Medicines Agency. Azilect [rasagiline (as mesilate)]: summary of product characteristics. 2005. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000574/WC500030048.pdf. Accessed 12 Sep 2014.
9. Hoy SM, Keating GM. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. [Erratum appears in Drugs. 2012;72:870-1]. Drugs. 2012;72(5):643-69.
10. Oldfield V, Keating GM, Perry CM. Rasagiline: a review of its use in the management of Parkinson's disease. Drugs. 2007;67(12):1725-47.
11. Siddiqui MAA, Plosker GL. Rasagiline. Drugs Aging. 2005;22(1):83-91 (discussion 3-4).
12. Weinreb O, Amit T, Riederer P, et al. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. Int Rev Neurobiol. 2011;100:127-49.
13. Gerlach M, Reichmann H, Riederer P. A critical review of evidence for preclinical differences between rasagiline and selegiline. Basal Ganglia. 2012;2(4 Suppl):S9-15.
14. Levitt P, Pintar JE, Breakefield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA. 1982;79(20):6385-9.
15. Kumar MJ, Andersen JK. Perspectives on MAO-B in aging and neurological disease: where do we go from here? Mol Neurobiol. 2004;30(1):77-89.
16. Bartl J, Muller T, Grunblatt E, et al. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm. 2014;121(4):379-83.
17. Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2004;24(10):1295-305.
18. Naoi M, Maruyama W, Inaba-Hasegawa K. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Rev Neurother. 2013;13(6):671-84.
19. Maruyama W, Naoi M. "70th Birthday Professor Riederer" induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy? J Neural Transm. 2013;120(1):83-9.
20. Mendzelevski B, Sprenger CR, Spiegelstein O, et al. Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study. Int J Clin Pharmacol Ther. 2014;52(3):192-201.
21. Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000;23(6):324-30.
22. Chen JJ, Ly A-V. Rasagiline: a second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am J Health Syst Pharm. 2006;63(10):915-28.
23. Bar-Am O, Weinreb O, Amit T, et al. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem. 2010;112(5):1131-7.
24. Perez-Lloret S, Rascol O. Safety of rasagiline for the treatment of Parkinson's disease. Expert Opin Drug Saf. 2011;10(4):633-43.
25. Panisset M, Chen JJ, Rhyhee SH. Parkinson's disease patients treated with rasagiline and antidepressants: assessing the occurrence of serotonin toxicity [abstract no. 848]. Mov Disord. 2011;26(Suppl 2):S284-5.
26. Chen JJ, Wilkinson JR. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? J Clin Pharmacol. 2012;52(5):620-8.
27. Goren T, Adar L, Sasson N, et al. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol. 2010;50(12):1420-8.
28. deMarcaida JA, Schwid SR, White WB, et al. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006;21(10):1716-21.
29. White WB, Salzman P, Schwid SR, et al. Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. Hypertension. 2008;52(3):587-93.
30. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61(4):561-6.
31. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59(12):1937-43.
32. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. [Erratum appears in N Engl J Med. 2011 May 12;364(19):1882]. N Engl J Med. 2009;361(13):1268-78.
33. Hauser RA, Silver D, Choudhry A, et al. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease. Mov Disord. 2014;29(8):1028-34.
34. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241-8.
35. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947-54.
36. Zhang L, Zhang Z, Chen Y, et al. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial. Int J Neuropsychopharmacol. 2013;16(7):1529-37.
37. Wilson RE, Seeberger LC, Silver D, et al. Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment. Neurolog. 2011;17(6):318-24.
38. Zambito Marsala S, Vitaliani R, Volpe D, et al. Rapid onset of efficacy of rasagiline in early Parkinson's disease. Neurol Sci. 2013;34(11):2007-13.
39. Stocchi F, Investigators A. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease. Eur J Neurol. 2014;21(2):357-60.
40. Biglan KM, Schwid S, Eberly S, et al. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord. 2006;21(5):616-23.
41. Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009;24(4):564-73.
42. Stocchi F, Rabey JM. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Eur J Neurol. 2011;18(12):1373-8.
43. Reichmann H, Jost WH. Efficacy and tolerability of rasagiline in daily clinical use: a post-marketing observational study in patients with Parkinson's disease. Eur J Neurol. 2010;17(9):1164-71.
44. Perez-Lloret S, Rey MV, Monstastruc JL, et al. Adverse drug reactions with selegiline and rasagiline compared to levodopa and ropinirole: a study in the French pharmacovigilance database [abstract no. 603]. Mov Disord. 2013;28(Suppl 1):S214.
45. Solis-Garcia del Pozo J, Minguez-Minguez S, de Groot PWJ, et al. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease. Expert Opin Drug Saf. 2013;12(4):479-86.
46. Viallet F, Pitel S, Lancrenon S, et al. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease. Curr Med Res Opin. 2013;29(1):23-31.
47. Zagmutt FJ, Tarrants ML. Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline. Int J Neurosci. 2012;122(7):345-53.
48. Goetz CG, Schwid SR, Eberly SW, et al. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006;66(9):1427-9.
49. Haycox A, Armand C, Murteira S, et al. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation. Drugs Aging. 2009;26(9):791-801.
50. Farkouh RA, Wilson MR, Tarrants ML, et al. Cost-effectiveness of rasagiline compared with first-line early Parkinson disease therapies. Am J Pharm Benefits. 2012;4(3):99-107.
51. Hudry J, Rinne JO, Keranen T, et al. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. Ann Pharmacother. 2006;40(4):651-7.
52. Thanvi BR, Lo TC. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J. 2004;80(946):452-8.